Engineered immune cells take on pancreatic cancer in early trial
NCT ID NCT07425483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called CAR-NK cells (CL-NK-003) in 9 people with advanced pancreatic cancer that has not responded to standard therapies. The main goal is to check safety and find the right dose. Researchers will also watch for signs that the treatment shrinks tumors or slows the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Ancient acupressure meets modern medicine: can ear stimulation replace standard Anti-Nausea drugs?
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New oral drug targets Cancer's growth engine in advanced tumours
- New imaging compound targets Hard-to-Spot cancers